Go Live for the Diagnostic Pathway for Larotrectinib

Decorative image of abstract gene-related design

On 21st April 2020, NICE announced that Larotrectinib has been made available via the Cancer Drugs Fund for treatment of NTRK fusion-positive solid tumours which meet a set of criteria.

NICE final appraisal document
www.nice.org.uk/guidance/indevelopment/gid-ta10229

Cancer Drugs Fund
www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list

Following this announcement, we are pleased to confirm that phase 1 NTRK testing is available to clinicians within our region through the North East and Yorkshire GLH using the Illumina Trusight RNA fusion panel.

Patients are eligible for testing in phase 1 if their diagnosis is in one of the 5 groups below
 

 

Testing group

 

   1

 

Four cancers in which NTRK gene fusion incidence is very high (>90%):

–  Infantile fibrosarcoma
–  Congenital mesoblastic nephroma
–  Mammary-variant salivary gland cancer
–  Secretory breast cancer

 

   2

 

Three cancers in which NTRK gene fusion incidence is between 5 and 25%:

–  Gastro-intestinal stromal tumours (GISTs)
–  Thyroid cancers
–  Spitzoid neoplasms

 

   3

 

Children (0-16 years) with solid tumours being treated in Principal Treatment Centres

 

   4

 

Teenagers (16-18 years) with solid tumours

 

   5

 

Young adults (18-25) with solid tumours

 

 

If you wish to request testing please complete a request form and send with the sample to your local GLH laboratory.

Share this story

Share This

Copy Link to Clipboard

Copy